Vesicular trafficking mechanisms regulating granulocyte function

调节粒细胞功能的囊泡运输机制

基本信息

  • 批准号:
    10225236
  • 负责人:
  • 金额:
    $ 43.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-12-03 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary: Intracellular vesicular transport is essential for all aspects of neutrophil physiology and defects in this mechanism leads to disease in humans. In neutrophils, vesicular trafficking is associated with the processes of exocytosis, phagocytosis, signaling and transmigration; however, the molecular mechanisms that regulate mobilization of the different neutrophil secretory organelles require further elucidation. We have identified several key regulators of neutrophil granule trafficking, including the small GTPase Rab27a and its effectors JFC1 and Munc13-4. We have also identified WASH as a neutrophil factor that regulates cytoskeleton remodeling, vesicular trafficking and exocytosis. Furthermore, we have pioneered the development of systems biology approaches to analyze vesicular dynamics and actin remodeling in granulocytes. Finally, we have identified a novel mechanism of late endosomal maturation that involves the interaction between the calcium sensor Munc13-4 and the late endosomal SNARE protein syntaxin 7 (STX7), to regulate TLR9 signaling and downstream neutrophil functions. Here, we use innovative quantitative methods to elucidate the mechanisms regulating vesicular transport associated with exocytosis, phagocytosis and late endosomal maturation in neutrophils. We also propose to use novel small-molecule inhibitors of Rab27a-JFC1 and Munc13-4-STX7 binding to investigate mechanisms of vesicular transport and to elucidate neutrophil function in disease using in vivo models of systemic inflammation. The central goal of this grant is to elucidate the vesicular transport mechanisms that govern neutrophil pro-inflammatory processes, develop translational approaches to interfere with these processes and provide preclinical validation for their use to attenuate systemic inflammation. Since dysregulated neutrophil activation is injurious to the host and neutrophil secretory proteins play fundamental roles in the damage to the endothelium associated with endotoxemia, sepsis and sterile inflammation, these studies have important physiological significance and potential clinical applications. We hypothesize that the differential regulation of vesicular transport by Rab27a and its effectors is an essential mechanism to determine specific neutrophil functions and responses to insult. We also propose that small-molecule modulators of specific vesicular transport pathways will prevent some of the deleterious consequences of neutrophil activation during systemic inflammation. To test our hypotheses we propose the following Specific Aims: 1) Define the mechanisms that differentially regulate vesicular trafficking, actin-dependent propulsion and blockage, and exocytosis of neutrophil granule subsets; 2) Establish the molecular mechanisms regulating endosomal maturation, endosomal function and nucleic acid-sensing TLR-signaling in neutrophils; 3) Develop mechanistic and translational approaches to regulate neutrophil vesicular trafficking pathways and migration for the control of systemic inflammation. The proposed research will elucidate the molecular mechanisms regulating vesicular transport in neutrophils and lead to new strategies to treat inflammatory diseases.
项目概述:细胞内囊泡转运对于中性粒细胞生理学的各个方面都是必不可少的, 这种机制的缺陷会导致人类疾病。在中性粒细胞中,囊泡运输与 胞吐作用、吞噬作用、信号传导和迁移的过程;然而, 调节不同中性粒细胞分泌细胞器的动员需要进一步阐明。我们有 确定了中性粒细胞颗粒运输的几个关键调节因子,包括小的GTTRab 27 a及其 效应器JFC 1和Munc 13 -4。我们还发现WASH是一种调节细胞骨架的中性粒细胞因子 重塑、囊泡运输和胞吐作用。此外,我们还率先开发了 生物学方法来分析粒细胞中的囊泡动力学和肌动蛋白重塑。我们终于有 确定了一种新的内体晚期成熟机制,涉及钙离子与核内体之间的相互作用。 传感器Munc 13 -4和晚期内体SNARE蛋白突触融合蛋白7(STX 7),以调节TLR 9信号传导, 下游中性粒细胞功能。在这里,我们使用创新的定量方法来阐明机制 调节与胞吐、吞噬和晚期内体成熟相关的囊泡转运, 中性粒细胞我们还建议使用Rab 27 a-JFC 1和Munc 13 -4-STX 7的新型小分子抑制剂 结合研究囊泡转运机制和阐明疾病中中性粒细胞的功能, 全身性炎症的体内模型。这项资助的中心目标是阐明 控制中性粒细胞促炎过程的机制,开发翻译方法来干扰 并为它们用于减轻全身性炎症提供临床前验证。以来 中性粒细胞活化失调对宿主有害,中性粒细胞分泌蛋白起着重要作用。 在与内毒素血症、败血症和无菌性炎症相关的内皮损伤中的作用,这些 研究具有重要的生理意义和潜在的临床应用价值。我们假设 Rab 27 a及其效应物对囊泡转运的差异调节是确定 特异性中性粒细胞功能和对损伤的反应。我们还提出,小分子调节剂的具体 囊泡运输途径将防止在运输过程中中性粒细胞活化的一些有害后果。 全身性炎症为了验证我们的假设,我们提出了以下具体目标:1)定义 差异调节囊泡运输、肌动蛋白依赖性推进和阻断的机制,以及 中性粒细胞颗粒亚群的胞吐作用; 2)建立调节内体 中性粒细胞中的成熟、内体功能和核酸敏感TLR信号传导; 3)发展机制 和翻译的方法来调节中性粒细胞囊泡运输途径和迁移, 全身性炎症这项研究将阐明调控囊泡的分子机制。 在中性粒细胞中的转运,并导致治疗炎症性疾病的新策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sergio Daniel Catz其他文献

Sergio Daniel Catz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sergio Daniel Catz', 18)}}的其他基金

2023 Phagocytes Gordon Research Conference and Gordon Research Seminar
2023吞噬细胞戈登研究大会暨戈登研究研讨会
  • 批准号:
    10683594
  • 财政年份:
    2023
  • 资助金额:
    $ 43.4万
  • 项目类别:
Neutrophil Mechanisms During Inflammation and Atherosclerosis
炎症和动脉粥样硬化期间的中性粒细胞机制
  • 批准号:
    10270898
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Neutrophil lineage in inflammation
炎症中的中性粒细胞谱系
  • 批准号:
    10470237
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10470238
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10651780
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10270895
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Neutrophil lineage in inflammation
炎症中的中性粒细胞谱系
  • 批准号:
    10270894
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Neutrophil Mechanisms During Inflammation and Atherosclerosis
炎症和动脉粥样硬化期间的中性粒细胞机制
  • 批准号:
    10470241
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Neutrophil Mechanisms During Inflammation and Atherosclerosis
炎症和动脉粥样硬化期间的中性粒细胞机制
  • 批准号:
    10651790
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:
Neutrophil lineage in inflammation
炎症中的中性粒细胞谱系
  • 批准号:
    10651774
  • 财政年份:
    2021
  • 资助金额:
    $ 43.4万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 43.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 43.4万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 43.4万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 43.4万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 43.4万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 43.4万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 43.4万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 43.4万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 43.4万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 43.4万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了